Penumbra

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Penumbra and other ETFs, options, and stocks.

About PEN

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. 

CEO
Adam Elsesser
CEOAdam Elsesser
Employees
4,700
Employees4,700
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
2004
Founded2004
Employees
4,700
Employees4,700

PEN Key Statistics

Market cap
13.51B
Market cap13.51B
Price-Earnings ratio
76.16
Price-Earnings ratio76.16
Dividend yield
Dividend yield
Average volume
615.62K
Average volume615.62K
High today
$344.45
High today$344.45
Low today
$341.70
Low today$341.70
Open price
$342.45
Open price$342.45
Volume
722.83K
Volume722.83K
52 Week high
$362.41
52 Week high$362.41
52 Week low
$221.26
52 Week low$221.26

Stock Snapshot

Penumbra(PEN) stock is priced at $344.39, giving the company a market capitalization of 13.51B. It carries a P/E multiple of 76.16.

On 2026-03-02, Penumbra(PEN) stock traded between a low of $341.70 and a high of $344.45. Shares are currently priced at $344.39, which is +0.8% above the low and -0.0% below the high.

The Penumbra(PEN)'s current trading volume is 722.83K, compared to an average daily volume of 615.62K.

In the last year, Penumbra(PEN) shares hit a 52-week high of $362.41 and a 52-week low of $221.26.

In the last year, Penumbra(PEN) shares hit a 52-week high of $362.41 and a 52-week low of $221.26.

PEN News

TipRanks 3d
Boston Scientific Secures New Credit Facilities for Acquisition

An announcement from Boston Scientific ( (BSX) ) is now available. On February 26, 2026, Boston Scientific entered into a new $3 billion five-year revolving cr...

TipRanks 5d
Hold Rating Maintained on Penumbra Amid Strong Results but Limited Visibility Ahead of Boston Scientific Acquisition

Needham analyst Michael Matson has maintained their neutral stance on PEN stock, giving a Hold rating on February 18. Michael Matson has given his Hold rating...

Nasdaq 5d
Penumbra Inc. Bottom Line Climbs In Q4

(RTTNews) - Penumbra Inc. (PEN) announced a profit for its fourth quarter that Increases, from last year The company's earnings came in at $47.34 million, or $...

Penumbra Inc. Bottom Line Climbs In Q4

Analyst ratings

79%

of 19 ratings
Buy
21.1%
Hold
78.9%
Sell
0%

More PEN News

TipRanks 5d
Penumbra reports Q4 adjusted EPS $1.18, consensus $1.11

Reports Q4 revenue $385.4M, consensus $367.18M. Given the proposed acquisition of Penumbra (PEN) by Boston Scientific (BSX), the company will not be providing f...

People also own

Based on the portfolios of people who own PEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.